The type III secretion system as a source of novel antibacterial drug targets.
Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Department of Immunology, University of Washington, Seattle, Washington 98195, USA. klinet@u.washington.edu
Toni
T
Kline
Heather B
HB
Felise
Sarah
S
Sanowar
Samuel I
SI
Miller
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism*; D001426:Bacterial Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods; D029968:Escherichia coli Proteins / Q000737:chemistry / Q000276:immunology / Q000378:metabolism; D006801:Humans; D000069296:Type III Secretion Systems
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D029968:Escherichia coli Proteins; C114344:PAS protein, E coli; D000069296:Type III Secretion Systems